Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.
Follow-Up Questions
Eagle Pharmaceuticals Inc (EGRX)'in P/E oranı nedir?
Eagle Pharmaceuticals Inc 'in P/E oranı 1.3589 'dir
EGRX hissesinin fiyat performansı nasıl?
EGRX 'in mevcut fiyatı $3.06 'dir, son işlem günde 0% decreased etti.
Eagle Pharmaceuticals Inc için ana iş temaları veya sektörler nelerdir?
Eagle Pharmaceuticals Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 3 analist Eagle Pharmaceuticals Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 3 güçlü al, 3 al, 1 tut, 0 sat ve 3 güçlü sat içermektedir
